Autosomal dominant Parkinson disease 4

This phase 3 trial is testing whether adding a targeted therapy called Sacituzumab tirumotecan (Sac-TMT) to standard chemotherapy and immunotherapy (pembrolizumab) can better eliminate cancer before surgery in people with high-risk, early-stage triple-negative or hormone-receptor…

This study tests whether adding a personalized mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can stop advanced melanoma from growing or spreading. About 160 people with stage III or IV melanoma that cannot be removed by surgery will receive either the vaccine plus…

This phase 3 trial tests whether adding the experimental drug sacituzumab tirumotecan (sac-TMT) to standard immunotherapy (pembrolizumab) and a targeted therapy (bevacizumab) helps people with metastatic cervical cancer live longer. About 1,000 participants whose cancer has sprea…

This phase 3 trial tests whether adding the experimental drug MK-2870 to the standard immunotherapy pembrolizumab helps people with advanced non-small cell lung cancer live longer compared to pembrolizumab alone. The study enrolls about 614 adults whose tumors have high PD-L1 lev…

This phase 3 trial tests whether a new drug (MK-2870), alone or with another drug (pembrolizumab), works better than standard treatments for people with a common type of advanced breast cancer (HR+/HER2-). About 1,200 participants whose cancer has worsened after hormone therapy w…

This study tests whether a new drug, sacituzumab tirumotecan (Sac-TMT), given alone or with pembrolizumab, helps people with advanced triple-negative breast cancer live longer or keep their cancer from growing. About 1,000 adults whose cancer has spread and who have not had prior…

This study tests a new targeted therapy pill called MK-1084, alone or with other drugs, for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. The goal is to see if the treatment is safe and can shrink tumors. About 130 participan…

This study tests whether adding an experimental mRNA vaccine (V940) to the immunotherapy drug pembrolizumab (Keytruda) can keep lung cancer from returning after surgery. It includes 680 people with stage II to IIIB non-small cell lung cancer whose tumors did not fully respond to …

This study tests several new drug combinations, with or without the immunotherapy pembrolizumab, in people with advanced esophageal cancer that has continued to grow after standard treatment. About 230 participants will receive different drug regimens to see which are safest and …

This phase 2 trial is testing whether giving the immunotherapy drug pembrolizumab (Keytruda) along with chemotherapy before surgery can eliminate all signs of cancer in people with resectable stage II to IIIB non-small cell lung cancer. About 60 participants will receive the comb…

This phase 3 trial is testing whether a targeted drug (trastuzumab deruxtecan) combined with immunotherapy (rilvegostomig or pembrolizumab) works better than standard chemotherapy plus pembrolizumab for people with advanced or recurrent endometrial cancer that has a specific prot…

This study tests several new drug combinations, including pembrolizumab (an immunotherapy), with or without chemotherapy, in people with advanced non-small cell lung cancer who have not had prior treatment. The goal is to see if these combinations can shrink tumors and control th…

This Phase 2 study tests two new antibody-drug conjugates (R-DXd and I-DXd) against standard chemotherapy in 96 people with advanced nonsquamous non-small cell lung cancer that has worsened after prior immunotherapy and chemotherapy. These 'guided missiles' deliver a cancer-killi…

This early-stage trial is testing an experimental drug called MK-0472, alone or combined with the immunotherapy Keytruda or another experimental drug MK-1084, in people with advanced or metastatic solid tumors. The main goals are to check safety, find the right dose, and see how …

This early-phase trial is testing a new experimental drug called BNT3212, alone or with another drug (pumitamig), in 375 adults with advanced solid tumors who have no other treatment options. The main goals are to check safety, find the right dose, and get an early look at whethe…

This phase 3 study is testing whether adding an experimental pill called calderasib (MK-1084) to the immunotherapy drug pembrolizumab (Keytruda) works better than pembrolizumab alone for people with advanced non-small cell lung cancer that has a KRAS G12C mutation and high PD-L1 …

This study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…

This study tests whether adding sacituzumab tirumotecan (Sac-TMT) to pembrolizumab helps people with advanced or recurrent endometrial cancer live longer without the cancer getting worse. About 1,100 participants with a specific type of endometrial cancer (pMMR) will receive eith…

This study tests new experimental drugs combined with standard chemotherapy and immunotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery or has spread. About 160 participants will receive the combination to …

This study tests two new drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. About 210 participants will receive either an experimental antibody-drug conjugate plus chemotherapy, or a stand…

This early-stage trial is testing a new cancer vaccine called BNT116, alone or with other drugs, in people with advanced non-small cell lung cancer. The main goal is to find a safe dose and check for side effects. About 320 participants will be enrolled across several groups, inc…

This early-phase study tests a new imaging drug called [18F]MK-0947 that works with PET scans to show where a protein called α-synuclein builds up in the brain—a hallmark of Parkinson's disease. Researchers will check safety and how well the tracer works in 22 adults (some with P…

This study is testing a new blood test to help doctors diagnose Parkinson's disease and similar brain disorders more accurately and earlier. Researchers will use a technique called RT-QuIC to detect misfolded proteins in blood samples from 458 participants, including healthy peop…

This study is testing whether a blood test can detect Parkinson's disease early, before symptoms become severe. Researchers will measure specific proteins (α-synuclein) in tiny particles from nerve cells in the blood of 600 people with Parkinson's and 600 healthy controls. The go…

This study is testing three new radioactive tracers that light up alpha-synuclein clumps in the brain during PET/CT scans. Researchers want to see if these scans can accurately diagnose Parkinson's disease and related disorders. 500 adults with suspected or confirmed Parkinson's …

This early-phase study tests a new radioactive tracer called 11C-HY-2-15, designed to detect abnormal alpha-synuclein protein in the brain. Researchers will scan 70 adults with multiple system atrophy, Parkinson's disease, progressive supranuclear palsy, or healthy volunteers to …

This study aims to develop computer models that can help diagnose and monitor Parkinson's disease by analyzing eye movements and walking patterns. Researchers will collect data from 100 people with Parkinson's or similar conditions using special devices. The goal is to make diagn…

This large study is testing many different drug combinations, including the immunotherapy pembrolizumab, in people with advanced non-small cell lung cancer. The goal is to see which treatments work best based on specific tumor features like PD-L1 levels and histology. Over 1,000 …

This study follows 214 people in China with multiple system atrophy, a rare and fast-worsening brain disease that affects movement and automatic body functions. Researchers will track symptoms over time to learn how the disease progresses and what factors influence it. The goal i…

This study explores whether the gut's nervous system can reveal early signs of Parkinson's disease. Researchers will analyze gut tissue and microbiome samples from 60 people aged 45-75 during routine colonoscopies. The goal is to find biomarkers that reflect brain changes, not to…

This study follows 650 people with early Parkinson's disease or a sleep condition called idiopathic REM sleep behavior disorder (iRBD). Researchers use brain scans, heart tests, and fluid samples to track changes over time. The goal is to better understand how these conditions de…

This study aims to collect health information from 100,000 people with Parkinsonian disorders in China over 10 years. Participants use an online platform to report symptoms, quality of life, and other health details every 3 months. The goal is to better understand how the disease…

This study is screening 2,000 people aged 50 to 99 who may have a higher risk of developing Parkinson's disease. Researchers will follow participants for five years to track early changes in risk markers and symptoms. The goal is to better understand how Parkinson's develops and …